Biocon trades with traction on the bourses

Biocon is currently trading at Rs. 430.45, up by 2.90 points or 0.68% from its previous closing of Rs. 427.55 on the BSE.

The scrip opened at Rs. 428.00 and has touched a high and low of Rs. 436.60 and Rs. 426.00 respectively. So far 58620 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 497.40 on 22-Jan-2014 and a 52 week low of Rs. 255.00 on 04-Mar-2013.

Last one week high and low of the scrip stood at Rs. 449.00 and Rs. 414.25 respectively. The current market cap of the company is Rs. 8597.00 crore.

The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 18.79% and 20.24% respectively.

Syngene, a wholly owned subsidiary of Biocon, and Baxter International, a leading global pharmaceutical company have collaborated to establish the Baxter Global Research Center at Syngene, in Bangalore. The Center was inaugurated by Ghulam Nabi Azad, the Minister of Health and Family Welfare, Government of India.

The Baxter Global Research Center (BGRC) at Syngene, is a part of Baxter's global strategy of building R&D collaborations with strategic partners. This collaboration will support Baxter in the Research and Development of medical products and devices to serve patients both in India and around the world. The Syngene team, working closely with Baxter scientists, will engage in a wide range of R&D activities centered on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy.

Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.